

THZ2

Catalog No: tcsc3245



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1604810-84-5

Formula:

$C_{31}H_{28}ClN_7O_2$

Pathway:

Cell Cycle/DNA Damage

Target:

CDK

Purity / Grade:

>98%

Solubility:

DMSO : \geq 39 mg/mL (68.90 mM)

Observed Molecular Weight:

566.05


Product Description

THZ2 is a potent and selective **CDK7** inhibitor with **IC₅₀** of 13.9 nM.

IC50 & Target: IC50: 13.9 nM (CDK7)^[1]

In Vitro: THZ2 selectively targets CDK7 and potently inhibits the growth of triple-negative but not ER/PR⁺ breast cancer cells. THZ2 at low nanomolar doses also efficiently suppresses the clonogenic growth of TNBC cells with IC₅₀ of appr 10 nM. THZ2 induces apoptotic cell death in triple-negative but not ER/PR⁺ breast cancer cells or normal human cells^[1].

In Vivo: THZ2 (10 mg/Kg) markedly reduces the growth rate of tumors in mice and demonstrates an anti-tumor activity. Compared to vehicle-treated tumors, tumor tissues isolated from mice treated with THZ2 has reduced proliferation and increased apoptosis, as indicated by immunostaining against Ki67 and cleaved Caspase 3 respectively. THZ2 in NOD-SCID mice leads to reduced body weight, suggesting that THZ2 may be less well-tolerated in this particular mouse strain^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!